Anti‐b diminishes hyperlipidaemia and hepatic steatosis in hamsters and mice by suppressing the mTOR/PPARγ and mTOR/SREBP1 signalling pathways
British Journal of Pharmacology2024Vol. 182(5), pp. 1254–1272
Citations Over TimeTop 10% of 2024 papers
Yu Bian, Han Wu, Weitao Jiang, Xue Kong, Yüting Xiong, Ling-Hua Zeng, Feng Zhang, Jinglun Song, Chunlei Wang, Yang Yang, Xinyue Zhang, Yuning Zhang, Ping Pang, Tianqi Duo, Zhuo Wang, Tengfei Pan, Baofeng Yang
Abstract
In conclusion, our study has provided initial data of a novel low MW compound, Anti-b, designed and synthesised to target mTOR protein directly. Our results indicate that Anti-b may represent a novel class of drugs for the treatment of hyperlipidemia and hepatic steatosis.
Related Papers
- → Identification of a novel human long non-coding RNA that regulates hepatic lipid metabolism by inhibiting SREBP-1c(2017)102 cited
- → Effects of differential regional PM2.5 induced hepatic steatosis and underlying mechanism(2023)13 cited
- → Tributyltin promoted hepatic steatosis in zebrafish (Danio rerio) and the molecular pathogenesis involved(2015)45 cited
- → Flavonoids extracted from Linaria vulgaris protect against hyperlipidemia and hepatic steatosis induced by western-type diet in mice(2017)23 cited
- Expression and role of SCAP in models of cultured steatosis hepatocytes(2007)